The company also announced it has initiated AGLOW, a Phase 2 proof-of-concept study of VX-407 for the treatment of ADPKD. VX-407 is an investigational small molecule corrector that is designed to treat ADPKD in patients with a subset of PKD1 variants, estimated at up to approximately 10% of the overall ADPKD population. VX-407 is designed to target the underlying cause of ADPKD by correcting defective PC1 folding to restore function, thereby potentially reducing total kidney volume and preventing progression to kidney failure. AGLOW is a 52-week single-arm study that will evaluate the effect of VX-407 on height-adjusted total kidney volume in patients with a subset of variants of the PKD1 gene.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Leerink ups Vertex Pharmaceuticals to Outperform on stock pullback, solid growth
- Vertex Pharmaceuticals upgraded to Outperform from Market Perform at Leerink
- Vertex Pharmaceuticals: Strong Market Position and Growth Potential Drive Buy Rating
- Vertex Pharmaceuticals announces CASGEVY reimbursement agreement in Italy
- Vertex Pharmaceuticals: Strong Buy Rating Backed by Promising Pipeline and Strategic Positioning